Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 9;41(16):2372–2389. doi: 10.1038/s41388-022-02253-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — A qRT-qPCR analysis of UPK1A-AS1 expression in Panc-1 transfected with shNeg or shUPK1A-AS1 lentivirus. B Once the tumors reached 3 mm in diameter, xenograft subcutaneous model receiving an anti-IL8 neutralizing antibody (20 mg/kg) and oxaliplatin (5 mg/kg) once every 3 days. C Representative images of xenograft subcutaneous model. D The changes of tumor volume were monitored and shown. E Xenograft orthotopic model receiving the same treatment as subcutaneous model 12 days after implantation. F Representative IVIS images and pancreatic tumors in orthotopic xenograft model. G, H Analysis of luminescence intensity in orthotopic xenograft model. The relative luminescence intensity = (X_day27-X_day12)/average(shNeg_day27-shNeg_day12). I Analysis of orthotopic tumor volume. The results are presented as the mean ± SD. N = 5/per group, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns no significance.